Results 31 to 40 of about 2,026 (156)

The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging ‘nonmutational epigenetic reprogramming’ cancer hallmark

Computational and Structural Biotechnology Journal, 2023
SMDY3 is a histone-lysine N-methyltransferase involved in several oncogenic processes and is believed to play a major role in various cancer hallmarks. Recently, we identified ATM, BRCA2, CHK2, MTOR, BLM, MET, AMPK, and p130 as direct SMYD3 interactors ...
Candida Fasano, Martina Lepore Signorile, Elisabetta Di Nicola, Antonino Pantaleo, Giovanna Forte, Katia De Marco, Paola Sanese, Vittoria Disciglio, Valentina Grossi, Cristiano Simone   +9 more
doaj   +1 more source

SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner

Cell Death and Disease, 2023
Protein lysine methyltransferase SET and MYND domain-containing 3 (SMYD3) is aberrantly expressed in various cancer settings. The mechanisms that SMYD3 activates the expression of critical pro-tumoral genes in an H3K4me3-dependent manner have been well ...
Yi Zeng, Gang Ma, Fenglin Cai, Pengliang Wang, Han Liang, Rupeng Zhang, Jingyu Deng, Yong Liu   +7 more
doaj   +1 more source

SMYD3 associates with the NuRD (MTA1/2) complex to regulate transcription and promote proliferation and invasiveness in hepatocellular carcinoma cells

BMC Biology, 2022
Background SMYD3, a member of the SET and MYND domain-containing (SMYD) family, is a histone methyltransferase (HMT) and transcription factor that plays an important role in transcriptional regulation in human carcinogenesis.
Yang Yang, Rongfang Qiu, Siyu Zhao, Lin Shen, Bufu Tang, Qiaoyou Weng, Ziwei Xu, Liyun Zheng, Weiqian Chen, Gaofeng Shu, Yajie Wang, Zhongwei Zhao, Minjiang Chen, Jiansong Ji   +13 more
doaj   +1 more source

A SMYD3/ITGB6/TGFβ1 Positive Feedback Loop Promotes the Invasion and Adhesion of Ovarian Cancer Spheroids

Frontiers in Oncology, 2021
BackgroundImplantation metastasis is the main means of dissemination in ovarian cancer. Our previous studies showed that SET and MYND domain-containing protein 3 (SMYD3) expression was higher in ovarian cancer spheroids than in monolayers.
Yahui Jiang, Tianyu Zhou, Yiwen Shi, Weiwei Feng, Tianjiao Lyu   +4 more
doaj   +1 more source

SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription

Cell Death and Disease, 2022
Genetic abnormalities in histone methyltransferases (HMTs) frequently occur in diffuse large B-cell lymphoma (DLBCL) and are related to its progression. SET and MYND domain containing 3 (SMYD3) is an HMT that is upregulated in various tumors and promotes
Tian Tian, Jiwei Li, Di Shi, Yupeng Zeng, Baohua Yu, Xiaoqiu Li, Ping Wei, Xiaoyan Zhou   +7 more
doaj   +1 more source

Impact of Infection-Related Immune Responses on ANCA-Associated Vasculitis in Finns: A Mendelian Randomization Study. [PDF]

Genet Res (Camb)
Background ANCA‐associated vasculitis (AAV) includes microscopic polyarteritis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Studies have revealed that infection‐related immune responses could trigger vasculitis.
Zhang N, Ji C, Lv T, Bao X.
europepmc   +2 more sources

SMYD3 promotes the epithelial–mesenchymal transition in breast cancer [PDF]

Nucleic Acids Research, 2018
SMYD3 is a methylase previously linked to cancer cell invasion and migration. Here we show that SMYD3 favors TGF-induced epithelial– mesenchymal transition (EMT) in mammary epithelial cells, promoting mesenchymal and EMT transcription factors expression.
Claudio Fenizia, Cinzia Bottino, Silvia Corbetta, Raffaella Fittipaldi, Pamela Floris, Germano Gaudenzi, Silvia Carra, Franco Cotelli, Giovanni Vitale, Giuseppina Caretti   +9 more
openaire   +2 more sources

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality

iScience, 2020
Summary: SMYD3 is frequently overexpressed in a wide variety of cancers. Indeed, its inactivation reduces tumor growth in preclinical in vivo animal models.
Paola Sanese, Candida Fasano, Giacomo Buscemi, Cinzia Bottino, Silvia Corbetta, Edoardo Fabini, Valentina Silvestri, Virginia Valentini, Vittoria Disciglio, Giovanna Forte, Martina Lepore Signorile, Katia De Marco, Stefania Bertora, Valentina Grossi, Ummu Guven, Natale Porta, Valeria Di Maio, Elisabetta Manoni, Gianluigi Giannelli, Manuela Bartolini, Alberto Del Rio, Giuseppina Caretti, Laura Ottini, Cristiano Simone   +23 more
doaj   +1 more source

Targeting Smyd3 by next-generation antisense oligonucleotides suppresses liver tumor growth

iScience, 2021
Summary: The oncogenic function of suppressor of variegation, enhancer of zeste and MYeloid-Nervy-DEAF1-domain family methyltransferase Smyd3 has been implicated in various malignancies, including hepatocellular carcinoma (HCC).
Haroula Kontaki, Marina Koukaki, Maria Vasilarou, Antonis Giakountis, Elena Deligianni, Xiaolin Luo, Youngsoo Kim, Iannis Talianidis   +7 more
doaj   +1 more source

Putting SMYD3 on the MAP [PDF]

Science-Business eXchange, 2014
Stanford and GlaxoSmithKline report that SMYD3 acts in the cytoplasm to regulate the MAPK pathway and not in the nucleus as previously thought. The discovery implies that inhibiting the enzyme can counter activating mutations in MAPK pathway components such as KRAS.
openaire   +1 more source